Continuing Medical Education Program - Purchase Activities
The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for healthcare professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs and changes in therapeutics. The objectives of the program are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter CME Program is funded by fees paid by the activity participants. The Medical Letter is free of commercial influence and financial sponsorship.

  The Medical Letter Individual Activities — Online Only
I would like to order the following Per Issue Activities eligible for 2 credits each: $15/activity
3 or more: $10/activity
1603  (2 credits)   Expires 07/27/2021
Lumateperone (Caplyta) for Schizophrenia
Durysta - A Bimatoprost Implant for Glaucoma
Drugs Past Their Expiration Date
Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy
1604  (2 credits)   Expires 08/10/2021
IV Artesunate for Severe Malaria
Drugs for Menopausal Symptoms
1605  (2 credits)   Expires 08/24/2021
Phexxi - A Nonhormonal Contraceptive Gel
Ozanimod (Zeposia) for Multiple Sclerosis
Cenobamate (Xcopri) for Focal Seizures
1606  (2 credits)
Drugs for COPD
1607  (2 credits)
Influenza Vaccine for 2020-2021
A New Indication for Esketamine Nasal Spray (Spravato)
Canagliflozin and Lower Limb Amputations
1608  (2 credits)
Drugs for Migraine
1609  (2 credits)
Timing of Remdesivir for COVID-19
Lyumjev - A New Insulin Lispro for Diabetes
Caplacizumab (Cablivi) for iTTP
Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy
Two New Doses of Dulaglutide (Trulicity) for Diabetes
1610  (2 credits)
Antiviral Drugs for Influenza for 2020-2021
Large-Volume, Preservative-Free Albuterol Concentrate
New Benzodiazepine Warnings
New Warnings on NSAID Use in Pregnancy
Extended-Release Budesonide (Ortikos) for Crohn's Disease
1611  (2 credits)
Hydrochlorothiazide and Skin Cancer
Empagliflozin (Jardiance) for Heart Failure
Minocycline Foam (Zilxi) for Rosacea
Orphengesic Forte - An Old Analgesic Combination Returns
Two Drugs for Advanced HER2-Positive Breast Cancer
1612  (2 credits)
An EUA for Bamlanivimab - A Monoclonal Antibody for COVID-19
Remdesivir (Veklury) for COVID-19
Drugs for Acne
New Meningococcal Serogroup B Vaccination Guidelines
1613  (2 credits)
Drugs for Asthma
1614  (2 credits)
An EUA for Casirivimab and Imdevimab for COVID-19
An EUA for Baricitinib (Olumiant) for COVID-19
Ofatumumab (Kesimpta) for MS
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
1615  (2 credits)
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
An Asenapine Patch (Secuado) for Schizophrenia
1616  (2 credits)
FDA Authorizes Moderna COVID-19 Vaccine
Antibacterial Drugs for Community-Acquired Pneumonia
Semglee - A New Insulin Glargine for Diabetes
Encorafenib (Braftovi) for Metastatic Colorectal Cancer
1617  (2 credits)
Twirla - A New Contraceptive Patch
Pitolisant (Wakix) for Narcolepsy
Osilodrostat (Isturisa) for Cushing's Disease
Avapritinib (Ayvakit) for GIST
1618  (2 credits)
Drugs for Parkinson's Disease
1619  (2 credits)
Sodium Sulfate-Based Tablets (Sutab) for Colonoscopy Preparation
Vericiguat (Verquvo) for Heart Failure
Oliceridine (Olinvyk) - A New Opioid for Severe Pain
Ashwagandha Supplements
1620  (2 credits)
FDA Authorizes Johnson & Johnson COVID-19 Vaccine
Drugs for Multiple Sclerosis
1621  (2 credits)
An EUA for Bamlanivimab and Etesevimab for COVID-19
Oriahnn for Fibroid-Associated Heavy Menstrual Bleeding
Semaglutide (Ozempic) for Weight Loss
Low-Dose Colchicine for Coronary Artery Disease
Hypertension with Erenumab (Aimovig)
1622  (2 credits)
Drugs for Allergic Rhinitis and Allergic Conjunctivitis
1623  (2 credits)
Evinacumab (Evkeeza) for Homozygous Familial Hypercholesterolemia
Vibegron (Gemtesa) for Overactive Bladder
Fluvoxamine for COVID-19?
Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis
New Recommendations for Gonococcal Infection
1624  (2 credits)
Antibacterial Drugs for Lyme Disease
Loteprednol 0.25% (Eysuvis) for Dry Eye Disease
Plenity for Weight Management
MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine
1625  (2 credits)
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection
Tramadol Oral Solution (Qdolo) for Pain
Inhaled Mannitol (Bronchitol) for Cystic Fibrosis
Teprotumumab (Tepezza) for Thyroid Eye Disease
1626  (2 credits)
Drugs for Chronic Heart Failure
1627  (2 credits)
An EUA for Sotrovimab for Treatment of COVID-19
Viloxazine ER (Qelbree) for ADHD
Estetrol/Drospirenone (Nextstellis) - A New Combination Oral Contraceptive
Jatenzo - An Oral Testosterone for Hypogonadism
1628  (2 credits)
Aducanumab (Aduhelm) for Alzheimer's Disease
Semaglutide (Wegovy) for Weight Loss
Insect Repellents
1629  (2 credits)
An EUA for Tocilizumab (Actemra) for COVID-19
Dapagliflozin (Farxiga) for Chronic Kidney Disease
Sunscreens

 

ACCME The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Letter Inc. designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This Continuing Medical Education (CME) activity was planned and produced in accordance with the ACCME Essentials and Policies.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Your participation information will be shared with ABIM through PARS.

AAFP  The AAFP has reviewed The Medical Letter Continuing Education Program, and deemed it acceptable for AAFP credit. Term of approval is from 01/01/2021 to 12/31/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 52 AAPA Category 1 CME credits. Approval is valid from 5/2/2021 to 12/31/2022 . PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202250.

Accreditation Council on Pharmacy Education
The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Each exam is acceptable for 2.0 hour(s) of knowledge-based continuing education credit (0.2 CEU).